CRNX - Crinetics Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5549.36M
Enterprise Value 3451.04M
Trailing P/E N/A
Forward P/E 1-7.74
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)332.34
Price/Book (mrq)4.24
Enterprise Value/Revenue 3272.86
Enterprise Value/EBITDA 6-9.56

Trading Information

Stock Price History

Beta (5Y Monthly) N/A
52-Week Change 32.45%
S&P500 52-Week Change 325.85%
52 Week High 328.81
52 Week Low 314.33
50-Day Moving Average 323.19
200-Day Moving Average 319.64

Share Statistics

Avg Vol (3 month) 361.3k
Avg Vol (10 day) 386.4k
Shares Outstanding 524.2M
Float 7.72M
% Held by Insiders 15.63%
% Held by Institutions 1101.55%
Shares Short (Dec. 30, 2019) 41.84M
Short Ratio (Dec. 30, 2019) 424.24
Short % of Float (Dec. 30, 2019) 421.76%
Short % of Shares Outstanding (Dec. 30, 2019) 47.61%
Shares Short (prior month Nov. 28, 2019) 42.09M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec. 30, 2018
Most Recent Quarter (mrq)Sep. 29, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-2,906.78%

Management Effectiveness

Return on Assets (ttm)-18.82%
Return on Equity (ttm)-29.87%

Income Statement

Revenue (ttm)1.65M
Revenue Per Share (ttm)0.07
Quarterly Revenue Growth (yoy)-7.80%
Gross Profit (ttm)-22.05M
EBITDA -47.18M
Net Income Avi to Common (ttm)-44.37M
Diluted EPS (ttm)-1.84
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)131.67M
Total Cash Per Share (mrq)5.44
Total Debt (mrq)5.74M
Total Debt/Equity (mrq)4.43
Current Ratio (mrq)17.18
Book Value Per Share (mrq)5.35

Cash Flow Statement

Operating Cash Flow (ttm)-38.94M
Levered Free Cash Flow (ttm)-25.27M